Xellia
Pharmaceutical company in Denmark
From Wikipedia, the free encyclopedia
Xellia Pharmaceuticals ApS is a Danish pharmaceutical company specialising in the development and manufacture of active pharmaceutical ingredients (APIs) for anti-infective therapies. With over 120 years of experience, the company's fermentation-based production process is considered technically complex, requiring extensive process expertise developed over decades. Xellia supplies more than 500 pharmaceutical companies across over 80 countries and is a subsidiary of Novo Holdings.
| Company type | Anpartsselskab |
|---|---|
| Industry | Pharmaceuticals, health care[1] |
| Founded | 1903 |
| Headquarters | Copenhagen, Denmark |
Key people | Michael Kocher (CEO) |
| Products | Vancomycin, Bacitracin, Colistin, Daptomycin, Tobramycin, Amphotericin |
Number of employees | 1,800+ |
| Parent | New Xellia Group A/S (Novo Holdings) |
| Website | https://www.xellia.com |
Products
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are:[2]
| ATC | Substance | Structural formula | Formulation for sale | Production started |
|---|---|---|---|---|
| D06AX05 (WHO) (FK) J01XX10 (WHO) (FK) R02AB04 (WHO) (FK) QA07AA93 (WHO) (FK[permanent dead link]) |
Bacitracin (MT)[3][4] |  |
Bacitracin | 1952 |
| D06AX05 (WHO) (FK) J01XX10 (WHO) (FK) R02AB04 (WHO) (FK) QA07AA93 (WHO) (FK[permanent dead link]) |
Bacitracin (MT)[3][4] | |
Bacitracin zinc | 1958 |
| Colistimethate natrium (CMS) | ||||
| A07AA10 (WHO) (FK) J01XB01 (WHO) (FK) QJ51XB01 (WHO) (FK[permanent dead link]) |
Colistin |  |
Colistin sulfate | 1969 |
| J01X X09 | Daptomycin (MT)[3][5] |  |
Daptomycin | |
| R02AB30 (WHO) (FK) |  |
Gramicidin | ||
| A07AA05 (WHO) (FK) J01XB02 (WHO) (FK) S01AA18 (WHO) (FK) S02AA11 (WHO) (FK) S03AA03 (WHO) (FK[permanent dead link]) QJ51XB02 (WHO) (FK[permanent dead link]) |
Polymyxin B (MT)[3][6] |  |
Polymyxin B-sulfate | 1968 |
| J01GB01 (WHO) (FK) S01AA12 (WHO) (FK) |
Tobramycin (MT)[3][7] |  |
Tobramycin sulfate | 2005 |
| D06AX08 (WHO) (FK) R02AB02 (WHO) (FK) S01AA05 (WHO) (FK) |
Tyrothricin |  |
Tyrothricin | |
| A07AA09 (WHO) (FK) J01XA01 (WHO) (FK) |
Vancomycin (MT)[3][8] |  |
Vancomycin hydrochloride | 2003 |
| A01AB04 (WHO) (FK) A07AA07 (WHO) (FK) G01AA03 (WHO) (FK) J02AA01 (WHO) (FK) |
Amfotericin B (MT)[3][9] |  |
Amfotericin B | 1985 |
| J02AX04 (WHO) (FK) | Caspofungin (MT)[3][10] |  |
Caspofungin acetate | |
| D07AC17 (WHO) (FK) R01AD08 (WHO) (FK) R01AD58 (WHO) (FK) R03BA05 (WHO) (FK) |
Fluticasone (MT)[3][11] |  |
Fluticasone propionate | |
| D07AC13 (WHO) (FK) R01AD09 (WHO) (FK) R03BA07 (WHO) (FK) |
Mometasone (MT)[3][12] |  |
Mometasone furoate |
Discontinued products
Previously the company also produced:
| Ingredient | Produced |
|---|---|
| Neomycin | 1952-? |
| Tetracycline | 1961-? |
Partnerships
China-US Trade War
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war.[18]